Core Viewpoint - The stock of 3SBio (01530) rose nearly 7% in early trading, driven by Pfizer's registration of two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on Clinicaltrials.gov [1] Group 1: Clinical Trials and Developments - Pfizer registered two global Phase III clinical trials for PF-08634404, focusing on advanced non-small cell lung cancer (NSCLC) in comparison to Keytruda plus chemotherapy and metastatic colorectal cancer [1] - The clinical trials are expected to be rapidly initiated by Pfizer for NSCLC and other solid tumors, with exploration of PF-08634404 in monotherapy and combination therapy with other treatments, including ADCs [1] Group 2: Financial Aspects - In May, Pfizer secured the rights to 3SBio's PD-1/VEGF dual antibody with an upfront payment of $1.25 billion, milestone payments of up to $4.8 billion, and a double-digit percentage of sales [1] Group 3: Market Outlook - According to Zhongyou Securities, PF-08634404 is anticipated to become a cornerstone treatment in global oncology, highlighting its potential impact on the market [1]
港股异动 | 三生制药(01530)早盘涨近7% 辉瑞启动SSGJ-707两项全球三期临床试验